Morningstar.co.uk contains data, news and research on stocks and funds, unique commentary and independent Morningstar research on a wide range of investment products, as well as portfolio and asset allocation tools to help you make better investment decisions.
(Alliance News) – Hutchmed (China) Ltd reported Wednesday that its drugs Elunate and Sulanda have been added to a list of approved drugs by the Chinese regulatory agency.
The Hong Kong-based pharmaceutical company said the China National Healthcare Security Administration’s updated list of national reimbursement drugs for 2022 will continue to include Elunate, while Sulanda will now be added.
By joining the NRDL, the drugs will be available in all government hospital pharmacies in China.
Elunate was first included in the NRDL for the treatment of metastatic colon cancer in January 2020, while Sulanda was in China last December has been approved for the treatment of advanced non-pancreatic neuroendocrine.
Chief Executive Christian Hogg said, « We welcome the addition of Sulanda to the NRDL along with the renewal of Elunate. The NRDL has enabled novel therapies across the country for diseases with large patient populations. «
(Alliance News) – NFT Investments PLC announced Friday that it has a 25 percent stake in …
(Alliance News) – Iomart Group PLC announced on Friday that it is getting a new revolving …
(Alliance News) – Ncondezi Energy Ltd announced on Friday that it had its renewable energies …
UPDATED for November 2021: Wide-Moat tobacco giants are still at the forefront with returns of 8% and more,. ..
Funds focused on China, the US and technology outperformed in the first quarter of 2019, while a …
Would you like to secure a sustainable source of income and return? Take a look under the hood of your fund …
As the year draws to a close, let’s recap some key lessons from five busy days of news
BP has ambitious plans to tackle the carbon transition and continues to pay solid dividends
Talking about money can be uncomfortable and emotional, but talking about death and finance could get you …
Here’s a handy guide to the tools and research available to you are available to help you choose your own inv …
The Morningstar Star Rating for stocks is based on an analyst’s estimate of the fair value of a stock. It is a projection / opinion and not a statement of fact. Morningstar assigns star ratings based on an analyst’s estimate of the fair value of a stock. Four components determine the star rating: (1) our assessment of the company’s economic divide, (2) our estimate of the fair value of the share, (3) our uncertainty regarding this estimate of the fair value and (4) the current market price. This process culminates in a one-point star rating that is updated daily. A 5-star rating represents the belief that the stock has good value at its current price; it is not a 1-star share. If our assumptions are correct in the base case, then over time, generally within three years, the market price will approach our fair value estimate. Investments in securities are subject to market and other risks. Past performance of a security may or may not be maintained in the future and is not an indication of future performance. Detailed information on the Morningstar Star Rating for Stocks can be found here
The Quantitative Fair Value Estimate is Morningstar’s estimate of the dollar amount per share that a company’s equity is worth today. The quantitative fair value estimate is based on a statistical model derived from the fair value estimate that Morningstar’s equity analysts attribute to companies, which includes a financial forecast for the company. The quantitative fair value estimate is calculated daily. It is a projection / opinion and not a statement of fact. Investments in securities are subject to market and other risks. Past performance of a security may or may not be maintained in the future and is not an indication of future performance. You can find detailed information on the quantitative fair value estimate here
Keywords:
